Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
about
CIViC databasePP2A: The Achilles Heal in MDS with 5q DeletionTP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.Significance of oncogenes and tumor suppressor genes in AML prognosis.Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patientsPotential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.Appropriate Clinical Strategies for Breast Cancer Coexisting with Acute Myeloid Leukemia in the Genomic-Molecular Era: A Case Report.Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes.Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Novel drugs for older patients with acute myeloid leukemia.The molecular pathogenesis of the myelodysplastic syndromes.Acute Myeloid Leukemia With Myelodysplasia-Related Changes.Preparing Patients With Myelodysplastic Syndrome for Transplant When Is Pre-transplant Cytoreductive Therapy Appropriate?p53 as an Effector or Inhibitor of Therapy Response.Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.Hypomethylating Agents as a Therapy for AML.Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis.Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulationPotential use of compounds from sea cucumbers as MDM2 and CXCR4 inhibitors to control cancer cell growth
P2860
Q27612411-9094EDE9-0EF3-471E-AD02-874A127FD8DFQ27690852-F43A6CEC-D509-49D2-9C87-2892E59AB102Q27853319-DDA22E90-A781-4616-B84C-808945867CA3Q30250315-3C479175-909C-4BA1-A8D6-CA7522782293Q33427165-10A47EAD-16C5-4C32-84F2-53FA8AA5AB05Q33435980-AAC5C17D-9227-4D78-BDA5-055E17CF468DQ34398397-6017F0B7-B70C-4B43-BE45-D968D2D223EBQ35016534-FD4D934F-838E-4CCD-9B38-70AB487E8B3AQ36544120-50D1B0F7-2438-4C17-BE33-DD1901CFC88BQ36938430-46C237C2-738D-4111-970D-64585DD30471Q37046564-87DCC9C7-9244-4210-A964-395A0FF7EEF9Q37392696-4152C097-AFCA-49BE-9A80-31823F021357Q37688233-FB5D13D4-7317-44CA-AF4E-37FF4DD5AEF4Q38241761-3FFF6D7F-6607-438B-A8FC-EA036C8027BBQ38341998-5AEA9F27-19CC-45CE-97C7-70B0FDA8C2C9Q38526939-FCD2D58C-4E1A-45CC-B35B-992E5ED82FC8Q38540862-A1854158-5C44-4C89-9E4E-A8FF73C9B064Q38659283-68D7B6EF-4331-43BD-8B8B-B7DB9D36EE1FQ38797003-919AB77E-655B-4CF2-ACC3-661A20F91527Q38911864-D6D98155-8140-4C3B-8845-BC65F24F8CC8Q39942266-06B12307-BFF9-4D81-A1F9-6767588B1D7AQ40377702-C6F912B7-C83B-4807-B69D-1EB3904F6827Q41470921-F9DC1CB2-ED08-40D5-AE44-43FEF59A0923Q41572334-B0CE296E-10DE-45E6-AC21-D0DBF36A26F2Q42158416-E8FF5744-76B4-45C2-9D24-643E7C48329EQ47145985-B2D42EFD-478A-414B-B01F-2A83714289DDQ47158332-A435C9D6-53EE-46F6-93AA-D22633ACAD7CQ47548041-76892D34-6925-4FD5-B981-71D86AB2BCB4Q47629716-42E7557F-989F-409A-AFEA-74F9AA588838Q48323548-A5E67B1E-FD34-44C2-AE8E-72E89079DE3BQ49401381-47EAF929-549D-434E-A1AC-D3C49AEED066Q51000809-6BD77800-1A93-48B8-A8DE-B46FD5C67DEAQ53064376-52C3FFFB-15F5-4A42-954B-08BFFFA48AD9Q54363269-F4A329D4-6604-4858-BF50-B70F0D370A78Q55364989-DE5A0F77-95D9-4553-B0A8-04444A836AD7Q55515597-0868EDEB-46AE-46A7-AE3A-7A1379D0D7BCQ57476629-A1D556FF-B2A9-494F-9AD6-EC5824A61DD5Q58796650-FFA28254-CD3E-4117-8AE2-A0B0D2BA2F17
P2860
Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@ast
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@en
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@nl
type
label
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@ast
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@en
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@nl
prefLabel
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@ast
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@en
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@nl
P2093
P50
P3181
P1433
P1476
Prognostic value of TP53 gene ...... emia treated with azacitidine.
@en
P2093
Cecile Bally
Hugues de The
Lionel Adès
Marie Sebert
Marie-Joelle Mozziconacci
Virginie Eclache
P3181
P356
10.1016/J.LEUKRES.2014.03.012
P577
2014-07-01T00:00:00Z